KRAS
ENSG00000133703
Target class
Enzyme
Chromosome
12
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Target name
- KRAS
- Gene name
- KRAS proto-oncogene, GTPase
- Gene symbol
- KRAS
- Previous gene symbols
- KRAS2
- Protein name
- GTPase KRas (EC 3.6.5.2) (K-Ras 2) (Ki-Ras) (c-K-ras) (c-Ki-ras) [Cleaved into: GTPase KRas, N-terminally processed]
- KRAS1
- K-Ras4B
- Gene biotype
- Protein coding
- Gene family
- RAS type GTPase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 30.74
- Tissue specificity (Gini)
- 0.228
- Tissue specificity (tau)
- 0.575
- KEGG gene identifiers
- hsa:3845
- Protein interaction confidence
- 0.859354
- Protein interaction partners
- 206
- R-HSA-6802946
- R-HSA-6802955
- R-HSA-8951936
- R-HSA-9648002
- R-HSA-9649948
- R-HSA-9674555
- R-HSA-9680350
- R-HSA-9753510
- R-HSA-9753512
- End position
- 25250936
- Start position
- 25205246
- Chromosome
- 12
- Strand
- Reverse
- Cell membrane
- Lipid-anchor
- Cytoplasmic side . Endomembrane system . Cytoplasm, cytosol .
- SUBCELLULAR LOCATION: [Isoform 2B]: Cell membrane
- Lipid-anchor .
- Cytosol
- PubMed 22431598
- PubMed 23698361
- PubMed 29239724
- PubMed 28619714
- Tissue specificity (tau)
- 0.574723
- Expression inequality (Gini)
- 0.228286
Expression in transcripts per million
- Nerve - Tibial
- 30.74
- Brain - Cerebellar Hemisphere
- 25.09
- Esophagus - Muscularis
- 22.17
- Esophagus - Mucosa
- 21.55
- Esophagus - Gastroesophageal Junction
- 20.19
Expression in transcripts per million
- Nerve - Tibial30.74
- Brain - Cerebellar Hemisphere25.09
- Esophagus - Muscularis22.17
- Esophagus - Mucosa21.55
- Esophagus - Gastroesophageal Junction20.19
- Lung19.76
- Vagina18.42
- Bladder18.35
- Colon - Transverse17.91
- Artery - Tibial17.65
- Brain - Cerebellum17.42
- Cells - EBV-transformed lymphocytes17.05
- Brain - Frontal Cortex (BA9)16.95
- Cells - Cultured fibroblasts16.8
- Uterus16.68
- Colon - Sigmoid16.64
- Small Intestine - Terminal Ileum16.59
- Skin - Sun Exposed (Lower leg)16.3
- Cervix - Ectocervix16.2
- Skin - Not Sun Exposed (Suprapubic)15.93
- Artery - Coronary15.15
- Thyroid15.03
- Stomach14.98
- Fallopian Tube14.91
- Adipose - Subcutaneous14.68
And 29 more, listed on the interactive page.
- GO:0000165
- GO:0007265
- GO:0010628
- GO:0000139
- GO:0005737
- GO:0005741
- GO:0005789
- GO:0005829
- GO:0005886
- GO:0005925
- GO:0009898
- GO:0012505
- GO:0016020
- GO:0003924
- GO:0005515
- GO:0044877
Related records
Trials (105)
- A 2-part Phase 1/2 Open-label Trial on ODM-212
- A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
- A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
- A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
- A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
- A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab
- A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
- A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
- A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
- A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
- A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors